Investment Rating - The report initiates coverage with an OUTPERFORM rating, indicating a positive outlook for the company [2]. Core Insights - Auntea Jenny (Shanghai) Industrial is recognized as a leading fresh beverage company in China, having surpassed 10,000 stores by the end of 2025, making it the third brand in the industry to achieve this milestone [3][7]. - The report emphasizes that the fresh beverage industry is increasingly dominated by leading brands, with strong channel advantages allowing them to rapidly expand and innovate [3]. - The company aims to become a global leader in multi-brand fresh beverage groups, leveraging a light-asset model for rapid expansion [7]. Financial Projections - Revenue projections for the company are as follows: Rmb 3,285 million for Dec-24, Rmb 4,215 million for Dec-25, Rmb 4,918 million for Dec-26, and Rmb 5,632 million for Dec-27, reflecting growth rates of -2%, 28%, 17%, and 15% respectively [2]. - Net profit is expected to grow from Rmb 418 million in Dec-24 to Rmb 707 million in Dec-27, with growth rates of 0%, 28%, 16%, and 14% [2]. - The diluted EPS is projected to increase from Rmb 4.09 in Dec-24 to Rmb 6.72 in Dec-27 [2]. Business Model and Strategy - The company operates under a dual-brand strategy, with Auntea Jenny as the main brand and Tea Waterfall as a supporting brand, focusing on both domestic and international markets [4][16]. - The report highlights the company's successful expansion in northern China, attributed to its management philosophy of mutual benefit and resource sharing, as well as a focus on health-oriented products targeting specific consumer demographics [4][20]. - The company has established a low-barrier franchise model, allowing for rapid store expansion and a diverse franchisee base, which is crucial for sustainable growth [37]. Market Position and Competitive Landscape - Auntea Jenny has shown a strong performance in the fresh beverage market, with a compound annual growth rate (CAGR) of 57% in store numbers from 2020 to 2023, outpacing competitors [8][20]. - The report notes that the company has a significant presence in the northern market, with over half of its stores located in this region, which is a strategic advantage compared to other brands [18][20]. - The competitive landscape is characterized by increasing market concentration, with leading brands expected to gain more market share while regional brands coexist [3][4]. Future Growth Potential - The company plans to open 2,000 to 3,000 new stores in 2026, maintaining a steady expansion pace while focusing on improving growth quality [53]. - The report anticipates that the Tea Waterfall brand will accelerate its expansion, targeting lower-tier cities and leveraging the established supply chain of the main brand [52]. - The overseas expansion strategy is focused on developed markets, with successful store openings in Malaysia, the USA, and South Korea, indicating significant growth potential [52].

Investment Rating - The report maintains an "Outperform" rating for Mao Geping Cosmetics, with a target price of HKD 108.20, indicating a potential upside of 23.1% from the current price of HKD 87.95 [2][14]. Core Insights - The cosmetics industry has seen intensified competition since 2025, a trend expected to continue into 2026. Mao Geping is anticipated to sustain strong growth in the second half of 2025, driven by robust offline same-store sales and strong online growth, despite some weakening in household consumption [3][11]. - The company has signed a strategic partnership with L Catterton, aimed at global market expansion and establishing a premium beauty investment fund, which could enhance its brand penetration in overseas markets [4][12]. - Shareholders plan to reduce their holdings by up to 3.51% of the total share capital, which may temporarily affect market sentiment, but the company emphasizes that this will not change control and the long-term fundamentals remain strong [5][13]. Financial Performance Summary - Revenue projections for Mao Geping are RMB 5.101 billion for 2025, RMB 6.489 billion for 2026, and RMB 8.115 billion for 2027, reflecting year-on-year growth rates of 31.3%, 27.2%, and 25.0% respectively [3][11]. - Net profit attributable to the parent company is expected to be RMB 1.201 billion in 2025, RMB 1.494 billion in 2026, and RMB 1.848 billion in 2027, with growth rates of 36.4%, 24.4%, and 23.7% respectively [3][11]. - The company maintains a high gross profit margin of around 84% and a return on equity (ROE) of approximately 34.9% in 2024, projected to decrease slightly in the following years [9][10].

Investment Rating - The report recommends a positive investment outlook for the real estate sector, highlighting specific stocks in various categories such as development, commercial residential, property management, and cultural tourism [1]. Core Insights - The report emphasizes the shift in the real estate industry from a focus on quantity to a focus on quality, driven by the new requirements set forth during the "15th Five-Year Plan" period, which aims for high-quality development [1][13]. - It identifies six key tasks to achieve high-quality development, including optimizing affordable housing supply and enhancing property service quality [1][61]. Summary by Sections 1. High-Quality Development as a New Requirement - The report discusses the significant changes in the real estate market, transitioning from a supply-demand imbalance to a potential oversupply situation, necessitating a focus on high-quality development [3][6]. - It outlines the central government's shift in policy from reducing leverage and total volume to stabilizing the real estate market and promoting quality [6][7]. 2. Understanding High-Quality Development - The report defines high-quality development as essential for meeting the people's aspirations for a better life, advancing modernization, and facilitating the transformation of the real estate industry [22][24]. - It presents three major significances, four key requirements, and six essential tasks for high-quality development [21][28]. 3. Policy Expectations for the 15th Five-Year Plan - The report anticipates that future policies will focus on risk prevention, quality improvement, and transformation in the development sector [62]. - It emphasizes the need for a balanced approach between short-term market stabilization and long-term structural reforms [36][60]. 4. Six Key Tasks for High-Quality Development - The report outlines six tasks: optimizing affordable housing supply, promoting sustainable market development, reforming development and financing systems, enhancing housing quality, improving property service quality, and establishing a safety management system for the entire lifecycle of housing [61][62].

Investment Rating - The report assigns an "Outperform" rating to the company [2]. Core Insights - The company's high efficiency across the supply chain, channels, and marketing is the core reason for establishing itself as a leading brand, with expectations for continued market share growth. The reuse of brand, channel, and marketing advantages to expand product categories is anticipated to further unlock growth potential, with new products expected to exceed expectations [1][4]. Financial Summary - The company’s projected earnings per share (EPS) for 2025-2027 are estimated at 0.55, 0.68, and 0.82 RMB, respectively. A target price of 18.48 HKD is set for 2026, based on a 25x price-to-earnings (PE) ratio [2][9]. - Revenue projections are as follows: - 2023: 4,869.53 million RMB - 2024: 5,745.32 million RMB (up 7.4%) - 2025: 6,929.05 million RMB (up 18.0%) - 2026: 8,188.01 million RMB (up 20.6%) - 2027: 9,453.91 million RMB (up 18.2%) [3]. Business Structure and Market Position - The rice industry lacks a total volume logic, but there is potential for growth in the mid-to-high-end rice segment due to structural upgrades. The overall competition is fragmented, with a slow increase in industry concentration. Brands positioned in the mid-to-high-end segment benefit from brand barriers and profit margins that allow for better resource allocation [2][28]. - The company has established a strong market position, with a 4% share in the pre-packaged premium rice market, leading the segment against competitors [39][42]. Product Expansion and Growth Potential - The company has a clear path for product innovation, with successful launches in new categories like corn, which is expected to drive future growth. The introduction of new products such as corn juice packs is anticipated to contribute to revenue growth [4][10]. - The company is also focusing on expanding its product categories, with plans to introduce southern rice and other new products to tap into larger growth opportunities [4][10]. Competitive Advantages - The company has built a high-efficiency supply chain in key geographical areas, ensuring quality and price advantages for raw materials. Its direct-to-consumer (D2C) sales model and order-based production enhance product freshness, contributing to a significantly higher repurchase rate compared to industry averages [4][62]. - The company’s marketing strategies and brand positioning have resulted in a strong customer base, with a high repurchase rate of 39% for its rice products, significantly above the industry average of 26% [58][62].

Investment Rating - The investment rating for Lululemon Athletica is maintained at "Neutral" with a target price of $215.50, reflecting a potential upside of 1.5% from the current price of $211.72 [2][16]. Core Insights - The company reported a revenue of $7.46 billion for 3QFY25, which is a year-on-year increase of 7.0%. However, revenue growth is expected to slow in 4QFY25 due to calendar shifts, with management anticipating a narrowing of overall revenue growth compared to the previous quarter [4][13]. - The current CEO, Calvin McDonald, will step down in January 2026, and the board has appointed Marti Morfitt as Executive Chair, with Meghan Frank and Andre Maestrini serving as Co-CEOs until a permanent CEO is found [4][16]. - The gross margin for 3QFY25 was reported at 55.6%, a decrease of 290 basis points year-on-year, which was better than the previously guided impact of 410 basis points [5][14]. - The company is focusing on product innovation to revitalize its North American business, with plans to increase the proportion of new products in the Spring 2026 collection to 35% [6][15]. Financial Summary - Revenue projections for FY2025, FY2026, and FY2027 are $11.03 billion, $11.58 billion, and $12.14 billion, respectively, with year-on-year growth rates of 4.2%, 5.0%, and 4.9% [9][16]. - Net profit estimates for the same periods are $1.55 billion, $1.51 billion, and $1.60 billion, reflecting changes of -14.4%, -2.9%, and +6.1% year-on-year [9][16]. - The company has a strong cash flow position, holding $1.0 billion in cash with no debt as of the end of 3QFY25, and has approved a new $1 billion share repurchase authorization [5][14].

Investment Rating - The report assigns an "Outperform" rating to MP Materials, expecting a relative increase of over 10% compared to the benchmark index within the next 12-18 months [10]. Core Insights - The rare earth market fundamentals are improving, with potential for more favorable factors and strategic partnerships to emerge [1]. - Recent market pullbacks are viewed as a buying opportunity, as the market is tightening and the government is setting a price floor for rare earth prices [1]. - The company has established a collaboration with the U.S. Department of Defense and is forming a strategic joint venture with Saudi Arabia's Ma'aden to develop a rare earth refining facility [1]. - The demand for neodymium-praseodymium (NdPr) is expected to grow at an annual rate of 6-8% over the next decade, with supply growth slightly lagging behind this demand [2]. - NdPr prices have increased by nearly 40% year-to-date, driven by strong downstream demand, with further price increases anticipated [2]. Summary by Sections Market Overview - NdPr market fundamentals are robust, with both Chinese and international midstream producers actively expanding [2]. - The price of neodymium oxide is projected to reach $80 per kilogram in 2026, $85 in 2027, and $90 in 2028 [2]. Company Developments - The U.S. Department of Defense has set a price floor of $110 per kilogram for NdPr products, with a profit-sharing mechanism for any price increases above this level [3]. - The company is accelerating its magnet manufacturing capacity in the U.S. from 1,000 tons per year to 10,000 tons per year [3]. Production Guidance - The company expects NdPr concentrate production to remain flat year-over-year in Q4 2025, with a slight increase in NdPr oxide production [4]. - NdPr prices have reached $61 per kilogram in Q4 2025, with expectations for continued cost reductions [4]. - The company plans to start commissioning its new heavy rare earth separation facility in mid-2026, with an annual production capacity of 3,000 tons of dysprosium and terbium [4]. Supply Chain Dynamics - The geopolitical tensions surrounding the rare earth supply chain are viewed as a temporary relief, with China holding 90% of rare earth resources concentrated in two major deposits [4].

Investment Rating - The report assigns an "Outperform" rating to multiple stocks in the Hong Kong healthcare sector, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene [1][4][37]. Core Insights - The rollout of the "dual formulary" system, which includes the National Reimbursement Drug List (NRDL) and the inaugural Commercial Innovation Drug List, is expected to significantly benefit the innovative drug value chain. The NRDL added 114 drugs with an 88% success rate, up from 76% in 2024, while the commercial list includes 19 innovative drugs [7][40]. - The report highlights three key features of the new drug lists: a focus on innovation, addressing the needs of the elderly and children, and reinforcing the distinction between basic and commercial insurance coverage [7][40]. - The report expresses a long-term positive outlook on the innovative drug value chain, driven by state support for novel drugs and the inclusion of high-innovation therapies in the commercial insurance list [7][40]. Summary by Sections Stock Recommendations - The report lists several top picks for January 2026, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene, all rated as "Outperform" [1][4][37]. Market Performance - The December 2025 portfolio of Hong Kong "Golden Picks" saw an average decline of 12.4%, underperforming the Hang Seng Healthcare Index, which fell by 9.5% [5][38]. - Notable performers in December included WuXi AppTec, Akeso, and JD Health, which experienced smaller declines compared to the overall portfolio [5][38]. Industry Trends - The healthcare services sector is noted as undervalued, with companies like Hygeia and Jinxin Fertility showing strong performance due to ongoing market buy-backs [8][41]. - The report suggests monitoring the recovery opportunities in the consumer healthcare sector for 2026, particularly in light of low base effects [8][41]. Recent Developments - A series of business development (BD) deals in December 2025 indicates sustained interest from multinational corporations (MNCs) in the biotech and pharmaceutical sectors, with significant upfront payments and milestone agreements [10][43][44]. - The report emphasizes the attractiveness of the biotech sector following recent valuation resets, suggesting potential for pre-earnings catch-up trades [10][42].

Investment Rating - The report assigns an "Outperform" rating to the company, with a target price of 89.2 yuan based on a 40x PE valuation for 2026 [4][7]. Core Insights - The company is leveraging AI technology and a strategic focus on local markets to enhance its market share in the public examination sector, supported by a partnership with Fenbi [1][4]. - The projected net profits for the company are expected to be 312 million yuan, 438 million yuan, and 543 million yuan for the years 2025 to 2027, respectively, with corresponding EPS of 1.58 yuan, 2.23 yuan, and 2.76 yuan [4][7]. - The non-degree training business is anticipated to be the main revenue driver, with significant growth expected in the coming years [4][45]. Financial Summary - Total revenue is projected to grow from 247 million yuan in 2023 to 5,159 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 131.3% in 2024 [3][4]. - The net profit attributable to the parent company is expected to turn from a loss of 92 million yuan in 2023 to a profit of 543 million yuan by 2027 [3][4]. - The gross margin is expected to improve from 53.48% in 2024 to 57.16% in 2027, driven by enhanced operational efficiency and brand strength [12][9]. Company Development - The company transitioned from a traditional architectural design firm to a player in the vocational education sector, leveraging resources from its controlling shareholder, Huatu Hongyang [15][16]. - The establishment of Huatu Education Technology Co., Ltd. in 2023 marks a significant step in the company's focus on examination training and vocational skills [16][15]. Industry Analysis - The number of college graduates in China is projected to exceed 12 million by 2025, creating a sustained demand for public examination training [25][40]. - The public examination training market is expected to reach approximately 151 billion yuan in 2025, with a potential growth to 237 billion yuan by 2030 [40][43]. - The overall vocational education training market is forecasted to grow from 781 billion yuan in 2021 to 1,102 billion yuan by 2026, indicating a robust industry outlook [40][43]. Operational Analysis - The non-degree training segment accounted for 99% of the company's revenue in the first half of 2025, highlighting its dominance in the business model [45][56]. - The company has established a comprehensive network across 31 provinces, covering over 1,000 locations, which enhances its market presence and operational efficiency [57][45].

Investment Rating - The report assigns a target price of RMB 11.30 for the company based on a 2026 PE of 20X, reflecting its leading position and expected profit improvement trend [5][9]. Core Insights - The white chicken industry is expected to gradually recover in price, with the company focusing on the most profitable breeding segment, indicating a potential for continued sales growth and improved profitability per bird [2][5]. - The company is the largest grandparent meat breeder in China, holding approximately one-third of the domestic market, and has shown significant sales growth in parent breeders and chicks [5][18]. - The hog business is also expanding, with a gross profit margin of 25.5% in the first half of 2025, indicating a strong performance compared to peers [5][18]. - Profitability is anticipated to increase in 2026 as industry capacity reduces, leading to price recovery, particularly benefiting the company's breeding-focused operations [5][19]. Financial Summary - Total revenue is projected to decline from RMB 3,225 million in 2023 to RMB 2,989 million in 2025, before recovering to RMB 3,514 million in 2026 and RMB 3,873 million in 2027 [4]. - Net profit attributable to the parent company is expected to drop significantly to RMB 196 million in 2025, but rebound to RMB 625 million in 2026 and RMB 818 million in 2027 [4]. - The company’s earnings per share (EPS) are forecasted to be RMB 0.18 in 2025, RMB 0.56 in 2026, and RMB 0.74 in 2027, reflecting a recovery trend [5][9].

元旦"微度假"热度高 宏观研究 /[Table_Date] 2026.01.04 2026-01-06 国内高频指标跟踪（2026 年第 1 期） 本报告导读： 消费复苏动能较强，但投资、生产仍需政策进一步提振。 投资要点： 宏 观 周 报 请务必阅读正文之后的免责条款部分 宏 观 研 究 证 券 研 究 报 告 [Table_Summary] 元旦居民出行热度高，"微度假"是主流。跨区域人员流动以 19.5%的 同比增速创近期新高，铁路、水路客运增速领跑，中短途微度假成 主流，服务消费中游乐需求表现亮眼，但商品消费受年末翘尾效应 消退影响有所回落。其他高频数据显示，投资方面，地产销售边际 回落，不过其中一线城市限购放松释放部分需求，基建与开工建设 仍受新项目不足等因素制约。进出口方面，港口运行平稳，国内进 口运价与 BDI 指数走势分化。生产方面，多数行业开工率回落，呈 现分化态势，石化受成本抬升、汽车受需求回落影响表现平淡，锂 电、光伏中上游制造等新兴行业表现较好。物价上，PPI 商品价格普 遍回升，CPI 表现分化。流动性层面，人民币汇率升破 7.0 大关，资 金利率与国债收益率有所上行。 风险提示：贸 ...